All three have exciting programs on the way.
These companies are still in the early innings of their growth potential.
With multiple drugs on the market and revenue ramping up, the sky's the limit.
The no-cost trading platform's customers have their clear favorites, and they're more mainstream names than you might expect them to be.
These diamonds in the rough won't stay down.
When evaluating investments, it helps to keep quarterly performance in context.
Catalyst (CPRX) reports mixed results for the first quarter, wherein earnings miss and revenues beat estimates. Fycompa sales boost revenues. The company maintains revenue guidance. The stock surges 3%....
Catalyst (CPRX) delivered earnings and revenue surprises of -13.33% and 2.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Catalyst's (CPRX) revenues in the first quarter of 2023 are expected to have been driven by Firdapse sales. Updates on generic competition and the commercial launch of Fycompa are expected.
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.